Chest
ReviewsInterferons and Their Application in the Diseases of the Lung
Section snippets
Biological Effects of IFNs
To understand the mechanism of action of IFNs, it is useful to begin with a brief review of their physiology. IFNs do not normally circulate, are formed constitutively by most cells, and function physiologically by autocrine or paracrine mechanisms.5
The biological effects of IFNs result primarily from the enhanced expression of a group of genes and proteins in responsive cells that are involved in inflammatory and antimicrobial activities. α-IFNs constitute a family of proteins that are
Therapeutic Applications
For the past 40 years, various forms of IFNs have been evaluated as therapy in a number of malignant and nonmalignant diseases. The major oncologic indications for IFNs include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. IFNs have been increasingly employed in the therapy for patients with viral infections (including hepatitis C and condylomata acuminata) and multiple sclerosis. The therapeutic
Idiopathic Pulmonary Fibrosis
In contrast to normal repair, chronic inflammation in interstitial lung disease promotes fibroproliferation and the deposition of an extracellular matrix reflecting dysregulated and exaggerated tissue repair. The persistent imbalance in the expression of T helper (Th) type 2 cytokines (ie, interleukin [IL]-4 and IL-13) vs Th1 cytokines (IL-2 and IFN-γ) in the lung is a mechanism for the progression of pulmonary fibrosis. IFN-γ is a major Th1 cytokine and possesses profound regulatory activity
Small Cell Lung Cancer
Despite high initial response rates to chemotherapy, most patients with small cell lung cancer (SCLC) relapse shortly after discontinuing therapy, and a cure remains an elusive goal, even for patients with limited-stage disease. For this reason, investigators have turned to the evaluation of alternative treatment strategies for patients with this malignancy. Different IFN preparations were used, but none of the trials showed a significant prolongation of survival.27
IFN has been evaluated in
Malignant Mesothelioma
The natural history of malignant pleural mesothelioma (MPM) remains unchanged with a median survival time for patients of < 12 months. It is resistant to both chemotherapy and radiotherapy.34
The instillation of recombinant human IFN (rhu-IFN)-γ in the pleural cavity has been used with promising results to treat patients with MPM. From the original group of 22 consecutive patients, 19 could be evaluated. Four complete thoracoscopic histopathologic responses and one partial response were observed
Malignant Pleural Effusions
Malignant pleural effusions (MPEs) remain a distressing and symptomatic problem in cancer patients. In one postmortem series,40 MPEs were found in 15% of patients who died with malignancies. MPEs also are one of the leading causes of exudative effusions. Studies40 have demonstrated that 77% of exudative effusions are secondary to a malignancy. Once an MPE is diagnosed, appropriate therapy may provide symptomatic relief and improved quality of life.
MPEs cause severe symptoms in patients with
Respiratory Infections
More than a century after the discovery of Mycobacterium tuberculosis, mycobacterial infections are resurgent. Therapy, which until recently had seemed simple and straightforward, is now complicated by the emergence of drug-resistant organisms and immunocompromised hosts. Multidrug-resistant tuberculosis (MDR-TB) is a serious, life-threatening condition that is associated with a high degree of morbidity and mortality (about 70%).50 Adjuvant cytokines such as IL-2, IFN-γ, IL-12, and
Toxicity
IFNs, when used as a systemic pharmacologic agent, have certain toxic effects. Skin, neurologic, endocrine, and immune toxicities have been reported.3 IFN-α therapy may result in fatigue, fever, weight loss, and appetite loss. In addition, it can induce autoimmune diseases due to its immunomodulatory properties. Furthermore, there are some reports545556 in the literature that describe the development of sarcoidosis associated with IFN-α treatment.
Less commonly, various autoimmune processes have
Conclusion
IFNs are being investigated and applied in patients with various respiratory disorders, including interstitial lung diseases, lung cancer, malignant mesothelioma, malignant pleural effusions, and respiratory infections. Recent promising preliminary results for IPF patients treated with IFN-γ-1b should prompt further confirmatory, well-designed, multicenter trials. IFN-γ is emerging as an important cytokine for use in the treatment patients with infectious diseases, including pulmonary MDR-TB. A
References (58)
- et al.
Type I interferons and limitin: a comparison of structures, receptors, and functions
Cytokine Growth Factor Rev
(2001) - et al.
The interferon system: a bird's eye view of its biochemistry
J Biol Chem
(1992) Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer
Semin Oncol
(2001)- et al.
Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer: a randomized study
Eur J Cancer
(1994) - et al.
The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia
Chest
(1993) - et al.
Interferon instillation for malignant pleural effusion
Ann Oncol
(1993) - et al.
Recombinant interferon alpha-2b in the management of malignant pleural effusions
Chest
(1997) - et al.
Interferon instillation for malignant pleural effusions
Ann Oncol
(1993) - et al.
Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
Lancet
(1997) - et al.
Interferon-a therapy associated with the development of sarcoidosis
Chest
(1999)